Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Byrd, J. C.
Right arrow Articles by Heerema, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Byrd, J. C.
Right arrow Articles by Heerema, N. A.
[Cancer Research 63, 36-38, January 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Interphase Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia May Predict Response to Rituximab1

John C. Byrd2, Lisa Smith, Marcy L. Hackbarth, Ian W. Flinn, Donn Young, John H. Proffitt and Nyla A. Heerema

The Division of Hematology-Oncology [J. C. B., L. S.], and Departments of Biostatistics [D. Y.] and Pathology [N. A. H.], Ohio State University, Columbus Ohio 43210; Vysis Incorporated, Downers Grove, Illinois [M. L. H., J. H. P.]; and Division of Hematologic Malignancies, The Johns Hopkins University, Baltimore, Maryland [I. W. F.]

Select cytogenetic abnormalities such as del(17)(p13.1) and del(11)(q22-q23)predict rapid disease progression and inferior survival in chronic lymphocytic leukemia (CLL). We sought to determine the impact of the four most common interphase cytogenetic abnormalities in 28 CLL patients relative to response to three-times-a-week rituximab therapy. Abnormalities were noted in 25 of the 28 patients to include del(13)(q14.3) [n = 16 (57%)], del(11)(q22.3) [n = 10 (36%)], +12 [n = 6 (21%)], del(17)(p13.1) [n = 5 (18%)], and normal [n = 3 (11%)]. Only a minority of each of these occurred as sole abnormalities. To categorize patients into one specific group, we used the hierarchical order del(17)(p13.1) > del(11)(q22.3) > trisomy 12 > del(13)(q14.3) to prioritize. Response to rituximab was noted to vary by cytogenetic group: del(17)(p13.1), 0% [n = 5]; del(11)(q22.3), 66% [n = 9]; del(13)(q14.3), 86% [n = 7]; +12, 25% [n = 4], and normal, 0% [n = 3]. Response was significantly lower (P = 0.05) in patients with del(17)(p13.1) as compared with those with other abnormalities. These data suggest that interphase cytogenetics in CLL may be predictive of a response to rituximab therapy and provide support for additional studies validating risk-adapted therapy in this disease.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
B. Li, S. Shi, W. Qian, L. Zhao, D. Zhang, S. Hou, L. Zheng, J. Dai, J. Zhao, H. Wang, et al.
Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity
Cancer Res., April 1, 2008; 68(7): 2400 - 2408.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Byrd, S. O'Brien, I. W. Flinn, T. J. Kipps, M. Weiss, K. Rai, T. S. Lin, J. Woodworth, D. Wynne, J. Reid, et al.
Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Clin. Cancer Res., August 1, 2007; 13(15): 4448 - 4455.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Grever, D. M. Lucas, G. W. Dewald, D. S. Neuberg, J. C. Reed, S. Kitada, I. W. Flinn, M. S. Tallman, F. R. Appelbaum, R. A. Larson, et al.
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
J. Clin. Oncol., March 1, 2007; 25(7): 799 - 804.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Byrd, T. S. Lin, J. T. Dalton, D. Wu, M. A. Phelps, B. Fischer, M. Moran, K. A. Blum, B. Rovin, M. Brooker-McEldowney, et al.
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
Blood, January 15, 2007; 109(2): 399 - 404.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch
How I treat refractory CLL
Blood, February 15, 2006; 107(4): 1276 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. C. Byrd, J. G. Gribben, B. L. Peterson, M. R. Grever, G. Lozanski, D. M. Lucas, B. Lampson, R. A. Larson, M. A. Caligiuri, and N. A. Heerema
Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy
J. Clin. Oncol., January 20, 2006; 24(3): 437 - 443.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Raval, D. M. Lucas, J. J. Matkovic, K. L. Bennett, S. Liyanarachchi, D. C. Young, L. Rassenti, T. J. Kipps, M. R. Grever, J. C. Byrd, et al.
TWIST2 Demonstrates Differential Methylation in Immunoglobulin Variable Heavy Chain Mutated and Unmutated Chronic Lymphocytic Leukemia
J. Clin. Oncol., June 10, 2005; 23(17): 3877 - 3885.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
T. S. Lin, N. A. Heerema, J. Swenor, M. S. Lucas, M. E. Moran, C. M. Cheney, D. M. Lucas, D. Young, M. A. Caligiuri, M. R. Grever, et al.
A Phase II Study of the TNF-{alpha} Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.
Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 3469 - 3469.
[Abstract]

Home page
 BloodHome page
G. Lozanski, N. A. Heerema, I. W. Flinn, L. Smith, J. Harbison, J. Webb, M. Moran, M. Lucas, T. Lin, M. L. Hackbarth, et al.
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
Blood, May 1, 2004; 103(9): 3278 - 3281.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. J. Rush, A. Raval, P. Funchain, A. J. Johnson, L. Smith, D. M. Lucas, M. Bembea, T.-H. Liu, N. A. Heerema, L. Rassenti, et al.
Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets
Cancer Res., April 1, 2004; 64(7): 2424 - 2433.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. S. Farag, I. W. Flinn, R. Modali, T. A. Lehman, D. Young, and J. C. Byrd
Fc{gamma}RIIIa and Fc{gamma}RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
Blood, February 15, 2004; 103(4): 1472 - 1474.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. C. Byrd, S. Stilgenbauer, and I. W. Flinn
Chronic Lymphocytic Leukemia
Hematology, January 1, 2004; 2004(1): 163 - 183.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. F. Eisenbeis, M. A. Caligiuri, and J. C. Byrd
Rituximab: Converging Mechanisms of Action in Non-Hodgkin's Lymphoma?
Clin. Cancer Res., December 1, 2003; 9(16): 5810 - 5812.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.